Intuitive Surgical (NASDAQ:ISRG) Given New $435.00 Price Target at Piper Sandler

Intuitive Surgical (NASDAQ:ISRG - Free Report) had its price objective increased by Piper Sandler from $425.00 to $435.00 in a report released on Friday morning, Benzinga reports. They currently have an overweight rating on the medical equipment provider's stock.

Several other research firms have also commented on ISRG. Raymond James raised their target price on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an outperform rating in a report on Thursday, January 25th. BTIG Research upped their price objective on Intuitive Surgical from $412.00 to $421.00 and gave the stock a buy rating in a research report on Friday. StockNews.com downgraded Intuitive Surgical from a buy rating to a hold rating in a research note on Thursday, February 29th. Robert W. Baird reduced their price target on shares of Intuitive Surgical from $440.00 to $436.00 and set an outperform rating on the stock in a research note on Friday. Finally, Mizuho upped their price objective on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a neutral rating in a research report on Thursday, January 25th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $381.24.

Intuitive Surgical Trading Down 1.7 %

Shares of NASDAQ:ISRG traded down $6.29 on Friday, reaching $366.34. 3,966,068 shares of the company's stock were exchanged, compared to its average volume of 1,675,699. Intuitive Surgical has a twelve month low of $254.85 and a twelve month high of $403.76. The company has a fifty day moving average of $387.27 and a 200-day moving average of $342.60. The company has a market capitalization of $129.85 billion, a price-to-earnings ratio of 73.65, a PEG ratio of 5.81 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. The company's revenue was up 11.5% on a year-over-year basis. During the same quarter last year, the company earned $1.00 EPS. As a group, equities research analysts forecast that Intuitive Surgical will post 4.93 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Myriam Curet sold 4,318 shares of the stock in a transaction on Friday, January 26th. The shares were sold at an average price of $370.15, for a total transaction of $1,598,307.70. Following the transaction, the executive vice president now directly owns 189 shares of the company's stock, valued at $69,958.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Myriam Curet sold 4,318 shares of the firm's stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $370.15, for a total value of $1,598,307.70. Following the completion of the sale, the executive vice president now directly owns 189 shares in the company, valued at approximately $69,958.35. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Marshall Mohr sold 108,790 shares of the company's stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now directly owns 26,877 shares in the company, valued at $10,349,795.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 248,418 shares of company stock worth $95,927,097. 0.90% of the stock is owned by corporate insiders.

Institutional Trading of Intuitive Surgical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Intuitive Surgical by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 30,375,494 shares of the medical equipment provider's stock valued at $10,247,477,000 after buying an additional 507,267 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Intuitive Surgical by 1.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider's stock worth $5,726,102,000 after acquiring an additional 272,741 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Intuitive Surgical by 1.0% in the 1st quarter. Geode Capital Management LLC now owns 6,444,995 shares of the medical equipment provider's stock worth $1,642,287,000 after acquiring an additional 61,659 shares in the last quarter. Morgan Stanley raised its holdings in shares of Intuitive Surgical by 29.9% in the fourth quarter. Morgan Stanley now owns 5,866,613 shares of the medical equipment provider's stock valued at $1,556,706,000 after purchasing an additional 1,351,002 shares during the last quarter. Finally, Edgewood Management LLC lifted its position in shares of Intuitive Surgical by 7.9% during the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider's stock valued at $1,731,016,000 after purchasing an additional 374,667 shares in the last quarter. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.